21 – 30 of 324
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
- 2019
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article
-
Mark
Coagulation factor VIII is vital for increasing global coagulation after physical exercise
(
- Contribution to journal › Article
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Moderate haemophilia in focus
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review
-
Mark
Evolution of replacement therapy for von Willebrand disease : From plasma fraction to recombinant von Willebrand factor
(
- Contribution to journal › Scientific review